SG11201900361RA - Methods of treating prostate cancer - Google Patents
Methods of treating prostate cancerInfo
- Publication number
- SG11201900361RA SG11201900361RA SG11201900361RA SG11201900361RA SG11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA SG 11201900361R A SG11201900361R A SG 11201900361RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- applicant
- johnson
- road
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 Ill IOU 0 11101 010 11111 01 110 1 0 011101 0111 001 11111 010 1111 MEV OEM Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/023017 Al 01 February 2018 (01.02.2018) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) (71) — (72) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 31/454 (2006.01) A61P 35/00 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, International Application Number: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2017/044413 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 28 July 2017 (28.07.2017) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. English (84) Designated States (unless otherwise indicated, for every Publication Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/368,466 29 July 2016 (29.07.2016) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/369,239 01 August 2016 (01.08.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Applicant: JANSSEN PHARMACEUTICA NV TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). KM, ML, MR, NE, SN, TD, TG). Inventor; and Applicant: GOTTARDIS, Marco [US/US]; 9 Harris Declarations under Rule 4.17: Road, Princeton, New Jersey 08540 (US). — as to applicant's entitlement to apply for and be granted a patent (Rule 4. 17(ii)) Inventors: HAWKINS, Rebecca; 1400 McKean Road, — as to the applicant's entitlement to claim the priority of the Spring House, 19477 (PA). SNYDER, Linda; 1400 McK- earlier application (Rule 4 . 17 (iii)) can Road, Spring House, Pennsylvania 19477 (US). YA- MADA, Douglas H.; 1400 McKean Road, Spring House, Published: Pennsylvania 19477 (US). — with international search report (Art. 21(3)) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- sey 08933 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — = (74) = (81) = = = Title: METHODS OF TREATING 100- 80- o c 60- ..m Tb 40- • - = c ._ 'e,.. ' 20 - 0 - 20 . 4 PROSTATE CANCER = (54) = = = = - • -A- C4-2B -A- LnCaP • = = • • • ...vir ...•- -yr- LnCaP AR.TB -e- VCaP -N- 22Rv 1 — = 1-1 IN 1-1 O M N 0 --.... 00 1-1 0 N (57) 0 Figure 1. : Disclosed are methods -2 . . . . . -1 0 1 2 3 log [niraparib], All Niraparib inhibits the growth of human prostate tumor cell lines in vitro. of treating prostate cancer by administering niraparib to a subject in need thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368466P | 2016-07-29 | 2016-07-29 | |
| US201662369239P | 2016-08-01 | 2016-08-01 | |
| PCT/US2017/044413 WO2018023017A1 (en) | 2016-07-29 | 2017-07-28 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900361RA true SG11201900361RA (en) | 2019-02-27 |
Family
ID=59649991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900361RA SG11201900361RA (en) | 2016-07-29 | 2017-07-28 | Methods of treating prostate cancer |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US20180028521A1 (en) |
| EP (1) | EP3490560A1 (en) |
| JP (2) | JP2019522032A (en) |
| KR (1) | KR20190033599A (en) |
| CN (1) | CN109640991A (en) |
| AU (2) | AU2017302660B2 (en) |
| BR (1) | BR112019001398A2 (en) |
| CA (1) | CA3031705A1 (en) |
| CO (1) | CO2019000753A2 (en) |
| DO (1) | DOP2019000019A (en) |
| IL (1) | IL264443A (en) |
| MA (1) | MA45780A (en) |
| MX (1) | MX2019001224A (en) |
| NI (1) | NI201900009A (en) |
| PE (1) | PE20190403A1 (en) |
| PH (1) | PH12019500135A1 (en) |
| SG (1) | SG11201900361RA (en) |
| SV (1) | SV2019005822A (en) |
| UA (1) | UA124972C2 (en) |
| WO (1) | WO2018023017A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| JP2019522032A (en) | 2016-07-29 | 2019-08-08 | ヤンセン ファーマシューティカ エヌ．ベー． | How to treat prostate cancer |
| CN111801117A (en) * | 2017-12-27 | 2020-10-20 | 特沙诺有限公司 | Methods of treating cancer |
| JP7456942B2 (en) * | 2018-05-16 | 2024-03-27 | オンクターナル セラピューティクス，インコーポレイテッド | Selective Androgen Receptor Degrader (SARD) Ligands and Methods of Use The Same |
| US20210340122A1 (en) * | 2018-09-05 | 2021-11-04 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| WO2023001746A1 (en) * | 2021-07-19 | 2023-01-26 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| CN106008460B (en) | 2008-01-08 | 2022-08-12 | 默沙东公司 | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide |
| CA2723590C (en) | 2008-05-07 | 2017-06-27 | Cardioxyl Pharmaceuticals Inc. | Novel nitroso compounds as nitroxyl donors and methods of use thereof |
| WO2012009475A1 (en) | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
| EP3230472A4 (en) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| JP2019522032A (en) * | 2016-07-29 | 2019-08-08 | ヤンセン ファーマシューティカ エヌ．ベー． | How to treat prostate cancer |
| JOP20190244A1 (en) | 2017-04-13 | 2019-10-13 | Janssen Pharmaceutica Nv | Combination therapy for prostate cancer |
-
2017
- 2017-07-28 JP JP2019504790A patent/JP2019522032A/en not_active Withdrawn
- 2017-07-28 BR BR112019001398-9A patent/BR112019001398A2/en unknown
- 2017-07-28 KR KR1020197005783A patent/KR20190033599A/en not_active IP Right Cessation
- 2017-07-28 CA CA3031705A patent/CA3031705A1/en active Pending
- 2017-07-28 WO PCT/US2017/044413 patent/WO2018023017A1/en unknown
- 2017-07-28 AU AU2017302660A patent/AU2017302660B2/en active Active
- 2017-07-28 EP EP17754226.3A patent/EP3490560A1/en active Pending
- 2017-07-28 MA MA045780A patent/MA45780A/en unknown
- 2017-07-28 PE PE2019000269A patent/PE20190403A1/en unknown
- 2017-07-28 MX MX2019001224A patent/MX2019001224A/en unknown
- 2017-07-28 CN CN201780046876.1A patent/CN109640991A/en active Pending
- 2017-07-28 SG SG11201900361RA patent/SG11201900361RA/en unknown
- 2017-07-28 UA UAA201901979A patent/UA124972C2/en unknown
- 2017-07-28 US US15/663,082 patent/US20180028521A1/en not_active Abandoned
-
2018
- 2018-09-14 US US16/131,772 patent/US11207311B2/en active Active
-
2019
- 2019-01-18 PH PH12019500135A patent/PH12019500135A1/en unknown
- 2019-01-24 IL IL264443A patent/IL264443A/en unknown
- 2019-01-25 NI NI201900009A patent/NI201900009A/en unknown
- 2019-01-28 SV SV2019005822A patent/SV2019005822A/en unknown
- 2019-01-28 CO CONC2019/0000753A patent/CO2019000753A2/en unknown
- 2019-01-28 DO DO2019000019A patent/DOP2019000019A/en unknown
-
2021
- 2021-11-16 US US17/528,017 patent/US20220071979A1/en active Pending
- 2021-11-16 US US17/528,050 patent/US20220071980A1/en active Pending
-
2022
- 2022-05-25 JP JP2022084991A patent/JP2022122920A/en active Pending
- 2022-11-17 US US17/989,329 patent/US20230098047A1/en active Pending
- 2022-11-17 US US17/989,420 patent/US20230078160A1/en active Pending
- 2022-11-17 US US17/989,462 patent/US20230149380A1/en active Pending
-
2023
- 2023-05-05 AU AU2023202813A patent/AU2023202813A1/en active Pending
- 2023-09-13 US US18/466,547 patent/US20240000766A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20190403A1 (en) | 2019-03-13 |
| JP2022122920A (en) | 2022-08-23 |
| BR112019001398A2 (en) | 2019-05-07 |
| US20230149380A1 (en) | 2023-05-18 |
| US20190022079A1 (en) | 2019-01-24 |
| US20230078160A1 (en) | 2023-03-16 |
| CO2019000753A2 (en) | 2019-02-08 |
| US20220071980A1 (en) | 2022-03-10 |
| IL264443A (en) | 2019-02-28 |
| CN109640991A (en) | 2019-04-16 |
| MA45780A (en) | 2019-06-05 |
| DOP2019000019A (en) | 2019-09-30 |
| US20240000766A1 (en) | 2024-01-04 |
| NI201900009A (en) | 2019-05-10 |
| EP3490560A1 (en) | 2019-06-05 |
| MX2019001224A (en) | 2019-06-03 |
| US11207311B2 (en) | 2021-12-28 |
| PH12019500135A1 (en) | 2019-10-28 |
| UA124972C2 (en) | 2021-12-22 |
| KR20190033599A (en) | 2019-03-29 |
| SV2019005822A (en) | 2019-03-28 |
| US20230098047A1 (en) | 2023-03-30 |
| AU2023202813A1 (en) | 2023-05-25 |
| AU2017302660B2 (en) | 2023-04-20 |
| JP2019522032A (en) | 2019-08-08 |
| WO2018023017A1 (en) | 2018-02-01 |
| US20180028521A1 (en) | 2018-02-01 |
| US20220071979A1 (en) | 2022-03-10 |
| AU2017302660A1 (en) | 2019-01-24 |
| CA3031705A1 (en) | 2018-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201809630RA (en) | Nicotine particles | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201903032SA (en) | Methods and compositions related to nk cell and anti-pdl1 cancer therapies | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
| SG11201909041SA (en) | Anti-pd-l1 antibody and use thereof | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11201907207UA (en) | Pharmaceutical combinations comprising an anti-ly75 antibody | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |